Generation of duck hepatitis B virus polymerase mutants through site- directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-L- 2',3'-dideoxy-3'-thiacytidine] in vitro

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 8, 1996, Pages 1957-1960

  Fischer, Karl P ^a   Tyrrell, D L J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; METHIONINE; RNA DIRECTED DNA POLYMERASE; VALINE; VIRUS DNA;

AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; HEPATITIS B VIRUS; NONHUMAN; PLASMID; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTANT; VIRUS REPLICATION;

EID: 0029799423     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.8.1957     Document Type: Article

References (31)

1. Benhamou, Y., E. Dohin, F. Lunel-Fabiani, T. Poynard, J. M. Huraux, C. Katlama, P. Opolon, and M. Gentilini. 1995. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients. Lancet 345:396-397.
2. Boucher, C. A. B., N. Cammack, P. Schipper, R. Schuurman, P. Rouse, M. A. Wainberg, and J. M. Cameron. 1993. High-level resistance to (-) enantiomeric 2′-deoxy-3′-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 37:2231-2234.
3. Chang, C.-N., S.-L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C.-H. Tsai, and Y.-C. Cheng. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (±)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
4. Chang, C.-N., V. Skalski, J. H. Zhou, and Y.-C. Cheng. 1992. Biochemical pharmacology of (+) and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J. Biol. Chem. 267:22414-22420.
5. Coates, J. A., N. Cammack, H. J. Jenkinson, A. J. Jowett, M. I. Jowett, B. A. Pearson, C. R. Penn, P. L. Rouse, K. C. Viner, and J. M. Cameron. 1992. (-)-2′-Deoxy-3′-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36:733-739.
6. Coates, J. A., N. Cammack, H. J. Jenkinson, I. M. Mutton, B. A. Pearson, R. Storer, J. M. Cameron, and C. R. Penn. 1992. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob. Agents Chemother. 36:202-205.
7. Condreay, L. D., C. E. Aldrich, L. Coates, W. S. Mason, and T.-T. Wu. 1990. Efficient duck hepatitis B virus production by an avian liver tumor cell line. J. Virol. 64:3249-3258.
8. Condreay, L. D., R. W. Jansen, T. F. Powdrill, L. C. Johnson, E. W. Selleseth, M. T. Paff, S. M. Daluge, G. R. Painter, P. A. Furman, M. N. Ellis, and D. R. Averett. 1994. Evaluation of the potent anti-hepatitis B virus agent (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in a novel in vivo model. Antimicrob. Agents Chemother. 38:616-619.
9. Doong, S.-L., C.-H. Tsai, R. F. Schinazi, D. C. Liotta, and Y.-C. Cheng. 1991. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues. Proc. Natl. Acad. Sci. USA 88:8495-8499.
10. Gao, Q., Z. Gu, J. Hiscott, G. Dionne, and M. A. Wainberg. 1993. Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37:130-133.
11. Girones, R., and R. H. Miller. 1989. Mutation rate of the hepadnavirus genome. Virology 170:595-597.
12. Gosselin, G., R. F. Schinazi, J.-P. Sommadossi, C. Mathé, M.-C. Bergogne, A.-M. Aubertin, A. Kirn, and J. L. Imbach. 1994. Anti-human immunodeficiency virus activities of the β-L enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1292-1297.
13. Hart, G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Gray, R. E. Boehme, and J. M. Cameron. 1992. Effects of (-)-2′-deoxy-3′-thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694.
14. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
15. Lin, T. S., M. Z. Luo, M. C. Liu, S. B. Pai, G. E. Dutchman, and Y.-C. Cheng. 1994. Antiviral activity of 2′,3′-dideoxy-beta-L-5-fluorocytidine (beta-L-FddC) and 2′,3′-dideoxy-beta-L-cytidine (beta-L-ddC) against hepatitis B virus and human immunodeficiency virus type 1 in vitro. Biochem. Pharmacol. 47:171-174.
16. Lin, T. S., M. Z. Luo, M. C. Liu, S. B. Pai, G. E. Dutschman, and Y.-C. Cheng. 1994. Synthesis and biological evaluation of 2′,3′-dideoxy-L-pyrimidine nucleosides as potential antiviral agents against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). J. Med. Chem. 37:798-803.
17. Mandart, E., A. Kay, and F. Galibert. 1984. Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences. J. Virol. 49:782-792.
18. Paff, M. T., D. R. Averett, K. L. Prus, W. H. Miller, and D. J. Nelson. 1994. Intracellular metabolism of (-)- and (+)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in HepG2 derivative 2.2.15 (subclone P5A) cells. Antimicrob. Agents Chemother. 38:1230-1238.
19. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
20. Schalm, S. W., R. A. de Man, R. A. Heijtink, and H. G. Niesters. 1995. New nucleoside analogues for chronic hepatitis B. J. Hepat. 22(Suppl. 1):52-56.
21. Schinazi, R. F., G. Gosselin, A. Faraj, B. E. Korba, D. C. Liotta, C. K. Chu, C. Mathe, J. L. Imbach, and J. P. Sommadossi. 1994. Pure nucleoside enantiomers of β-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro. Antimicrob. Agents Chemother. 38:2172-2174.
22. Schinazi, R. F., R. M. Lloyd, Jr., M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
23. Severini, A., X.-Y. Liu, J. S. Wilson, and D. L. J. Tyrrell. 1995. Mechanism of inhibition of duck hepatitis B virus polymerase by (-)-β-L-2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 39:1430-1435.
24. Skalski, V., C.-N. Chang, G. Dutschman, and Y.-C. Cheng. 1993. The biochemical basis for the differential anti-human immunodeficiency virus activity of two cis enantiomers of 2′,3′-dideoxy-3′-thiacytidine. J. Biol. Chem. 268:23234-23238.
25. Staprans, S., D. D. Loeb, and D. Ganem. 1991. Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA. J. Virol. 65:1255-1262.
26. Sullivan, V., K. K. Biron, C. Talarico, S. C. Stanat, M. Davis, L. M. Pozzi, and D. M. Coen. 1993. A point mutation in the human cytomegalovirus DNA polymerase gene confers resistance to ganciclovir and phosphonylmethoxyalkyl derivatives. Antimicrob. Agents Chemother. 37:19-25.
27. Tatarowicz, W. A., N. S. Lurain, and K. D. Thompson. 1992. A ganciclovir-resistant clinical isolate of human cytomegalovirus exhibiting cross-resistance to other DNA polymerase inhibitors. J. Infect. Dis. 166:904-907.
28. Tisdale, M., S. D. Kemp, N. R. Parry, and B. A. Larder. 1993. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90:5653-5656.
29. Tyrrell, D. L. J. Unpublished data.
30. Tyrrell, D. L. J., K. P. Fischer, K. Sayani, W. Ian, and L. Jewell. 1993. Treatment of chimpanzees and ducks with lamivudine, 2′,3′-dideoxy-3′-thiacytidine, results in a rapid suppression of hepadnaviral DNA in sera. Clin. Invest. Med. 16(Suppl. 4):B77. (Abstract 487.)
31. Tyrrell, D. L. J., M. C. Mitchell, R. A. De Man, S. W. Schalm, J. Main, H. C. Thomas, J. Fevery, F. Nevens, P. Beraneck, and C. Vicary. 1993. Phase II trial of lamivudine for chronic hepatitis B. Hepatology 18:112A. (Abstract 224.)